Eye Care

Blindness and vision loss impact over 1 billion people around the world. From our first discovery in 1948 at Allergan, now part of AbbVie, our scientists have pioneered research on ocular diseases and treatment for the front and back of the eye.

Today we're building on our already broad and diverse portfolio with a focus on neurodegenerative diseases of the retina and ocular surface diseases, as well as investigating the genetic basis for certain eye diseases.

Each year more people will receive a vision-threatening diagnosis due to aging and lifestyle factors. Our robust research and development approach is anchored in improving the standards of care across multiple disease areas to make a meaningful difference for patients. 

 Our research interests include:

Improving standards for all
Bridging our understanding of biological processes and the genetic basis of human disease to accelerate ophthalmic drug discovery.

Finding new approaches
Leading innovation in long-acting therapeutic approaches via mechanism of action, sustained-release formulations or gene therapy to reduce the treatment burden. 

Collaboration in innovation
Working with colleagues across AbbVie to seize the scientific opportunity of innovation within oncology, immunology and neuroscience through knowledge of common disease pathways. 

State-of-the-art imagery
Applying state-of-the-art imaging modalities to monitor disease progression and therapeutic intervention to accelerate the translation of bench science to the clinic.

Strategic collaboration
Joining forces with innovative partners that complement our strengths, capabilities and commitments to eye care, including our work in chronic retinal diseases.